Joseph L. Benci

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

14h-index6.6kcitations46works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(27), Immune cells in cancer(9), Nanoplatforms for cancer theranostics(6), Glioma Diagnosis and Treatment(5), Immunotherapy and Immune Responses(5)

Publications46 total

Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S6 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Cancer Immunology Research·2025· 6 citedOpen Access
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity
Science Translational Medicine·2023· 23 cited
Measurement of LAG-3 Expression Across Multiple Staining Platforms With the 17B4 Antibody Clone
Archives of Pathology & Laboratory Medicine·2023· 3 citedOpen Access
Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction
Nature Cancer·2023· 95 cited
A multi‐omic single cell sequencing approach to develop a <scp>CD8</scp> T cell specific gene signature for <scp>anti‐PD1</scp> response in solid tumors
International Journal of Cancer·2022· 5 cited
Consistent measurement of LAG-3 expression across multiple staining platforms with the 17B4 antibody clone
2022· 2 citedOpen Access
DGKζ exerts greater control than DGKα over CD8 <sup>+</sup> T cell activity and tumor inhibition
OncoImmunology·2021· 13 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Michael Wichroski(17), Andy J. Minn(16), Si-Qi Liu(15), Louis Chupak(15), Joelle M. Onorato(15), Hongchen Qiu(15), Dana Banas(15), Ryan L. Powles(15), Gregory Locke(15), Abigail E. Witt(15), Huilin Qi(15), Lauren M. Zasadil(14), Patrick C. Gedeon(14), Kendall J. Condon(14), Suhasini Joshi(14), Shana Posy(14), Patrick Carlson(14), Alison Maier(14), Jiao Shen(14), Rakeeb Kureshi(14)